Sequenom Inc., a life sciences company providing innovative genetic analysis solutions, reported on March 8 that it had total revenues of $15.5 million and $55.9 million for the fourth quarter and full year of 2011, respectively. Net loss was $22.2 million, or 22 cents per share, and $74.2 million, or 75 cents per share, for the fourth quarter and full year, respectively.

“2011 was a pivotal year for Sequenom as the Sequenom Center for Molecular Medicine launched its cornerstone MaterniT21 prenatal laboratory-developed test and advanced a number of other important programs,” said Harry F. Hixson, chairman and CEO of Sequenom Inc. “The positive uptake from the launch of the MaterniT21 LDT and increasing early volumes for testing services since has set the tone for our expected growth and expansion during 2012.”

Fourth quarter revenues of $15.5 million in 2011 increased 13 percent over revenues of $13.8 million for the comparable period in 2010. Fourth quarter 2011 revenues from the genetic analysis operating segment were essentially flat year-over-year, while revenues from the Sequenom Center for Molecular Medicine diagnostics services operating segment grew more than 130 percent in the fourth quarter of 2011 from the prior year period.

The company’s Nasdaq symbol is SQNM.